Lake Street Capital assumed coverage on shares of Biodesix (NASDAQ:BDSX – Free Report) in a report issued on Friday, Marketbeat reports. The brokerage issued a buy rating and a $3.00 price target on the stock. Separately, Canaccord Genuity Group reaffirmed a buy rating and set a $3.50 target price on shares of Biodesix in a […]
Biodesix (NASDAQ:BDSX – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Biodesix has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call […]
Biodesix (NASDAQ:BDSX – Get Free Report) and Personalis (NASDAQ:PSNL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Institutional and Insider Ownership 21.0% of Biodesix shares are […]
Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 181,100 shares, a growth of 12.1% from the February 29th total of 161,500 shares. Based on an average daily trading volume, of 115,700 shares, […]
Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 196,700 shares, a growth of 32.9% from the January 15th total of 148,000 shares. Approximately 0.8% of the shares of the stock are sold short. Based on […]